In contrast to interference with the recall of preexisting CD8+ T cells, VZV-vax-specific CD4+ T cells did not appear to be impeded by preexisting antibodies, as IT injection of the gE-based VZV vaccine led to efficient recall of CD4+ T cell responses and at least partial tumor control. The gene discussed is CD8A; the disease is neoplasm.